Management of CMV Infection in Adults
For HIV-infected adults with CMV disease, initiate oral valganciclovir for most cases, reserving IV ganciclovir for severe tissue-invasive disease, and always start or optimize antiretroviral therapy (ART) concurrently to restore immune function. 1
Treatment Approach by Disease Manifestation
CMV Retinitis
For sight-threatening lesions (adjacent to optic nerve or fovea):
- Preferred: Ganciclovir intraocular implant PLUS oral valganciclovir 1
- Consider immediate intravitreous ganciclovir injection while arranging implant placement 1
For peripheral, non-sight-threatening lesions:
- Preferred: Oral valganciclovir alone 1
- Alternative options: IV ganciclovir, IV foscarnet, or IV cidofovir 1
Critical point: Even small peripheral lesions in ART-naïve patients should receive systemic anti-CMV therapy for 3-6 months until immune recovery occurs, as anti-CMV therapy reduces mortality in immunocompromised patients 1
CMV Colitis or Esophagitis
- Treatment: IV ganciclovir or foscarnet for 21-28 days OR until symptoms resolve 1
- Alternative: Oral valganciclovir if symptoms are mild enough to allow oral absorption 1
- Exception: May withhold therapy if only mild symptoms AND ART can be initiated/optimized soon 1
CMV Pneumonitis
- Treatment: IV ganciclovir, foscarnet, or cidofovir if CMV confirmed by histology/cytology 1
- Caveat: Limited data on treatment efficacy for outcomes 1
CMV Neurologic Disease
- Treatment: Combination ganciclovir PLUS foscarnet preferred for initial therapy 1
- Critical: Initiate therapy promptly for optimal response 1
- Caution: High toxicity rates with combination therapy 1
- ART timing: Consider delaying ART initiation until clinical improvement to avoid IRIS-related morbidity 1
Antiretroviral Therapy Integration
Start or optimize ART immediately for patients with CMV retinitis, gastrointestinal disease, or pneumonitis 1
- No evidence that ART worsens these manifestations 1
- Immune recovery is essential for long-term CMV control 1
Monitoring Requirements
For CMV Retinitis:
- Dilated indirect ophthalmoscopy:
- Monthly fundus photographs using standardized technique for optimal relapse detection 1
Laboratory Monitoring:
For ganciclovir or foscarnet:
For cidofovir:
- BUN, creatinine, urinalysis before each infusion 1
- Contraindicated if renal dysfunction or proteinuria detected 1
Key Adverse Effects
Ganciclovir/valganciclovir: Neutropenia, thrombocytopenia, nausea, diarrhea, renal dysfunction 1
Foscarnet: Anemia, nephrotoxicity, electrolyte abnormalities, seizures 2, 1
Cidofovir: Dose-related nephrotoxicity, hypotony, uveitis 1
Maintenance Therapy and Discontinuation
Discontinue chronic maintenance therapy when:
- CD4+ count sustained >100 cells/µL for 3-6 months on ART 1
- Decision made with ophthalmologist input 1
- Continue ophthalmologic monitoring every 3 months indefinitely 1
Reinstitute maintenance therapy if:
- CD4+ count decreases to <100 cells/µL 1
Important Clinical Pitfalls
Do NOT treat CMV viremia alone without organ involvement—not recommended outside clinical trials 1
Immune Recovery Uveitis (IRU): Occurs in first 4-12 weeks after ART initiation in patients with substantial CD4+ rise; treat with periocular or systemic corticosteroids 1
Drug resistance: Occurs at ~10% per person-year in ART era; suspect if early relapse or progression despite therapy 1
Systemic therapy protects contralateral eye—consider this when choosing between local vs. systemic treatment 1
Transplant Recipients (Non-HIV Context)
For solid organ and hematopoietic stem cell transplant recipients, management differs significantly:
Kidney transplant recipients:
- Prophylaxis with oral ganciclovir or valganciclovir for ≥3 months post-transplant (except donor-/recipient- seronegative) 3
- For serious/tissue-invasive disease: IV ganciclovir 3
- For non-serious disease in adults: IV ganciclovir OR oral valganciclovir 3
- All pediatric transplant CMV disease: IV ganciclovir 3
Emerging therapies: